Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease

Blennow, 2006, Alzheimer's disease, Lancet, 368, 387, 10.1016/S0140-6736(06)69113-7

Alzheimer, 1906, Über einen eigenartigen schweren Erkrankungsprozeβ der Hirnrincle, Neurol Central, 25, 1134

Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994

Karran, 2011, The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics, Nat Rev Drug Discov, 10, 698, 10.1038/nrd3505

Higgins, 2003, Transgenic mouse models of Alzheimer's disease: phenotype and application, Behav Pharmacol, 14, 419

Butterfield, 2002, Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review, Free Radic Res, 36, 1307, 10.1080/1071576021000049890

Furgerson, 2012, Model Hirano bodies protect against tau-independent and tau-dependent cell death initiated by the amyloid precursor protein intracellular domain, PloS One, 7, e44996, 10.1371/journal.pone.0044996

Lee, 2010, Antioxidant approaches for the treatment of Alzheimer's disease, Expert Rev Neurother, 10, 1201, 10.1586/ern.10.74

Caudle, 2008, Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease, Proteomics Clin Appl, 2, 1484, 10.1002/prca.200800043

Bertram, 2007, Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database, Nat Gen, 39, 17, 10.1038/ng1934

Sunaga, 1995, Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain, Neurosci Lett, 200, 133, 10.1016/0304-3940(95)12098-O

Butterfield, 2010, Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration, J Alzheimer's Dis, 20, 369, 10.3233/JAD-2010-1375

Butterfield, 2002, Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress, Free Radic Biol Med, 32, 1050, 10.1016/S0891-5849(02)00794-3

Uttara, 2009, Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options, Curr Neuropharmacol, 7, 65, 10.2174/157015909787602823

Newman, 2007, An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach, J Neurosci Res, 85, 1506, 10.1002/jnr.21275

Sultana, 2006, Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach, Neurobiol Dis, 22, 76, 10.1016/j.nbd.2005.10.004

Seidler, 2013, Basic biology of GAPDH, Adv Exp Med Biol, 985, 1, 10.1007/978-94-007-4716-6_1

Jenkins, 2006, High-resolution structure of human D-glyceraldehyde-3-phosphate dehydrogenase, Acta Crystallogr D Biol Crystallogr, 62, 290, 10.1107/S0907444905042289

Sirover, 1999, New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase, Biochim Biophys Acta, 1432, 159, 10.1016/S0167-4838(99)00119-3

Zheng, 2003, S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component, Cell, 114, 255, 10.1016/S0092-8674(03)00552-X

Tisdale, 2002, Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein kinase Ciota/lambda and plays a role in microtubule dynamics in the early secretory pathway, J Biol Chem, 277, 3334, 10.1074/jbc.M109744200

Patterson, 2005, Inositol 1,4,5-trisphosphate receptor/GAPDH complex augments Ca2+ release via locally derived NADH, Proc Natl Acad Sci USA, 102, 1357, 10.1073/pnas.0409657102

Chen, 1999, Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53, J Neurosci, 19, 9654, 10.1523/JNEUROSCI.19-21-09654.1999

Hara, 2006, GAPDH as a sensor of NO stress, Biochim Biophys Acta, 1762, 502, 10.1016/j.bbadis.2006.01.012

Hara, 2006, Neuroprotection by pharmacologic blockade of the GAPDH death cascade, Proc Natl Acad Sci USA, 103, 3887, 10.1073/pnas.0511321103

Bae, 2006, Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH, Proc Natl Acad Sci USA, 103, 3405, 10.1073/pnas.0511316103

Burke, 1996, Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH, Nat Med, 2, 347, 10.1038/nm0396-347

Verdier, 2008, Characterization of the interaction between Abeta 1-42 and glyceraldehyde phosphodehydrogenase, J Pept Sci, 14, 755, 10.1002/psc.998

Cumming, 2005, Amyloid beta induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease, FASEB J, 19, 2060, 10.1096/fj.05-4195fje

Schulze, 1993, Rat brain glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant cytoplasmic domain of Alzheimer's beta-amyloid precursor protein, J Neurochem, 60, 1915, 10.1111/j.1471-4159.1993.tb13420.x

Torres-Bugeau, 2012, Characterization of heparin-induced glyceraldehyde-3-phosphate dehydrogenase early amyloid-like oligomers and their implication in alpha-synuclein aggregation, J Biol Chem, 287, 2398, 10.1074/jbc.M111.303503

Tamaoka, 1996, Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Neurobiol Aging, 17, 405, 10.1016/0197-4580(96)00031-0

Oyama, 2000, Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation, Biochim Biophys Acta, 1479, 91, 10.1016/S0167-4838(00)00057-1

Verdier, 2005, Identification of synaptic plasma membrane proteins co-precipitated with fibrillar beta-amyloid peptide, J Neurochem, 94, 617, 10.1111/j.1471-4159.2005.03158.x

Naletova, 2008, Non-native glyceraldehyde-3-phosphate dehydrogenase can be an intrinsic component of amyloid structures, Biochim Biophys Acta, 1784, 2052, 10.1016/j.bbapap.2008.07.013

Mazzola, 2001, Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts, J Neurochem, 76, 442, 10.1046/j.1471-4159.2001.00033.x

Kornberg, 2010, GAPDH mediates nitrosylation of nuclear proteins, Nat cell Biol, 12, 1094, 10.1038/ncb2114

Colell, 2009, Novel roles for GAPDH in cell death and carcinogenesis, Cell Death Differ, 16, 1573, 10.1038/cdd.2009.137

Nakajima, 2007, The active site cysteine of the proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase is essential in oxidative stress induced aggregation and cell death, J Biol Chem, 282, 26562, 10.1074/jbc.M704199200

Iqbal, 2005, Tau pathology in Alzheimer disease and other tauopathies, Biochim Biophys Acta, 1739, 198, 10.1016/j.bbadis.2004.09.008

Higuchi, 2005, Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies, J Neurosci, 25, 9434, 10.1523/JNEUROSCI.2691-05.2005

Lee, 2005, Transgenic animal models of tauopathies, Biochim Biophys Acta, 1739, 251, 10.1016/j.bbadis.2004.06.014

Wang, 2005, Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein, FASEB J, 19, 869, 10.1096/fj.04-3210fje

Yang, 2008, Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis, Neurol Res, 30, 613, 10.1179/174313208X284124

Andreasen, 1998, Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study, J Neurol Neurosurg Psychiatry, 64, 298, 10.1136/jnnp.64.3.298

Andreasen, 2002, Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease, Peptides, 23, 1205, 10.1016/S0196-9781(02)00056-6